Normal citrated human plasma depleted of Factor VII using antibodies directed to FVII immobilized on agarose beads. Polyclonal antibody inhibitory to FVII was added to provide FVII neutralizing activity.

•Mild: 1-10 BU/ml •Moderate: ≥ 10-50 BU/ml •Strong: ≥ 50-200 BU/ml The inhibitor potency is measured by standard Bethesda activity assay.

PT (HemosIL PT-Fib): 46.6 sec APTT (HemosIL APTT-SP): 34.6 sec Fibrinogen (clottable): 2.94g/L FVII (activity): < 0.01U/ml FVII inhibitor activity (Bethesda assay): 27BU/ml

Bethesda assay performed at a 1:20 dilution, then mixed with an equal volume of normal plasma and incubated at 37ºC for 120 minutes. The FVII activity was measured by one stage clotting assay and the resiual FVII activity was calculated as a percentage activity compared to a buffer control run in parallel. The residual FVII activity is converted to Bethesda units using the Bethesda chart or graph. The Bethesda value derived (BU/ml) is multiplied by the initial dilution of the sample to obtain the corrected inhibitor concentration.

Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Normal citrated human plasma

Purified by immunoaffinity chromatography.

Supplied as a liquid in 20mM HEPES.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.